Unicycive shares plunge 39.1% after FDA repeats manufacturing deficiencies
AI Summary- Robbins LLP announced a shareholder class action against Unicycive Therapeutics.
- 39.1% was Unicycive’s June 30, 2026, share-price decline to $4.69.
- Investors purchased securities during the December 29, 2025-June 29, 2026, class period.